Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-26T01:37:30.285Z Has data issue: false hasContentIssue false
  • English
  • Français

P02.232 Impact of residual symptoms on outcomes in GAD: Evidence from placebo-controlled trials of venlafaxine er

Published online by Cambridge University Press:  16 April 2020

J.G.C. Rasmussen ,
D. Hacken ,
P. Meoni  and
C. White
J.G.C. Rasmussen
Affiliation:
Chaldon Road Surgery, Caterham; Consulting Statistician, Basingstoke, UKWyeth Ayerst CR&D, Paris, France
D. Hacken
Affiliation:
Chaldon Road Surgery, Caterham; Consulting Statistician, Basingstoke, UKWyeth Ayerst CR&D, Paris, France
P. Meoni
Affiliation:
Chaldon Road Surgery, Caterham; Consulting Statistician, Basingstoke, UKWyeth Ayerst CR&D, Paris, France
C. White
Affiliation:
Chaldon Road Surgery, Caterham; Consulting Statistician, Basingstoke, UKWyeth Ayerst CR&D, Paris, France

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Symposia
Information
European Psychiatry , Volume 15 , Issue S2: Congress of the Association of European Psychiatrists , October 2000 , pp. 384s
Copyright
Copyright © European Psychiatric Association 2000
Submit a response

Comments

No Comments have been published for this article.